Leerink Partners Upgrades Eli Lilly and Company (NYSE:LLY) to Outperform

Eli Lilly and Company (NYSE:LLY) was upgraded by Leerink Partners from a “market perform” rating to an “outperform” rating in a note issued to investors on Monday, Marketbeat reports. The brokerage currently has a $1,104.00 price target on the stock, up from their previous price target of $886.00. Leerink Partners’ target price suggests a potential upside of 11.80% from the company’s previous close.

LLY has been the subject of several other research reports. Berenberg Bank reissued a “hold” rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. HSBC raised their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $981.89.

Eli Lilly and Company Stock Up 2.2%

LLY opened at $987.48 on Monday. The firm has a market capitalization of $933.55 billion, a P/E ratio of 64.54, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a one year low of $623.78 and a one year high of $999.95. The company has a fifty day moving average price of $809.69 and a 200-day moving average price of $776.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the company earned $1.18 earnings per share. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its position in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Vanguard Group Inc. now owns 80,959,089 shares of the company’s stock worth $61,771,785,000 after purchasing an additional 551,659 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Laurel Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Finally, Norges Bank bought a new position in Eli Lilly and Company during the 2nd quarter valued at approximately $8,827,714,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.